Efficacy and safety of liposomal clarithromycin and its effect on pseudomonas aeruginosa virulence factors

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2694-2704

  Alhajlan, Mai ^a   Alhariri, Moayad ^a   Omri, Abdelwahab ^a  

^a LAURENTIAN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; CLARITHROMYCIN; VIRULENCE FACTOR;

ARTICLE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BIOFILM; BODY FLUID; COLONY FORMING UNIT; CONTROLLED STUDY; CYSTIC FIBROSIS; DEHYDRATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ENCAPSULATION; ENZYME ASSAY; HUMAN; HUMAN CELL; HYDRATION; LIGHT SCATTERING; LIPOSOMAL DELIVERY; LUNG ALVEOLUS EPITHELIUM; MICROBIAL ACTIVITY; MICROBIOLOGY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BIOFILMS; CELL LINE, TUMOR; CLARITHROMYCIN; CYSTIC FIBROSIS; EPITHELIAL CELLS; HUMANS; LIPOSOMES; LUNG; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; VIRULENCE FACTORS;

EID: 84877855980     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00235-13     Document Type: Article

References (91)

1. Hoiby N. 2011. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 9:32.
2. Uppaluri L, England SJ, Scanlin TF. 2012. Clinical evidence that V456A is a cystic fibrosis causing mutation in South Asians. J. Cyst. Fibros. 11: 312-315.
3. Sheikh HS, Tiangco ND, Harrell C, Vender RL. 2011. Severe hypercapnia in critically ill adult cystic fibrosis patients. J. Clin. Med. Res. 3:209-212.
4. Munder A, Wolbeling F, Kerber-Momot T, Wedekind D, Baumann U, Gulbins E, Tummler B. 2011. Acute intratracheal Pseudomonas aeruginosa infection in cystic fibrosis mice is age-independent. Respir. Res. 12: 148. doi:110.1186/1465-9921- 1112-1148.
5. Rogers GB, Hoffman LR, Doring G. 2011. Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. J. Cyst. Fibros. 10:387-400.
6. Ostedgaard LS, Meyerholz DK, Chen JH, Pezzulo AA, Karp PH, Rokhlina T, Ernst SE, Hanfland RA, Reznikov LR, Ludwig PS, Rogan MP, Davis GJ, Dohrn CL, Wohlford-Lenane C, Taft PJ, Rector MV, Hornick E, Nassar BS, Samuel M, Zhang Y, Richter SS, Uc A, Shilyansky J, Prather RS, McCray PB Jr, Zabner J, Welsh MJ, Stoltz DA. 2011. The DeltaF508 mutation causes CFTR misprocessing and cystic fibrosislike disease in pigs. Sci. Transl. Med. 3:74ra24. doi:10.1126/ scitranslmed .3001868.
7. Ntimbane T, Comte B, Mailhot G, Berthiaume Y, Poitout V, Prentki M, Rabasa-Lhoret R, Levy E. 2009. Cystic fibrosis-related diabetes: From CFTR dysfunction to oxidative stress. Clin. Biochem. Rev. 30:153-177.
8. Cohen TS, Prince A. 2012. Cystic fibrosis: A mucosal immunodeficiency syndrome. Nat. Med. 18:509-519.
9. Knapp JM, Wood AB, Phuan PW, Lodewyk MW, Tantillo DJ, Verkman AS, Kurth MJ. 2012. Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in DeltaF508 cystic fibrosis transmembrane conductance regulator protein. J. Med. Chem. 55:1242-1251.
10. Clunes MT, Boucher RC. 2007. Cystic fibrosis: The mechanisms of pathogenesis of an inherited lung disorder. Drug Discov. Today Dis. Mech. 4:63-72.
11. Hauser AR, Jain M, Bar-Meir M, McColley SA. 2011. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Microbiol. Rev. 24:29-70.
12. O'Malley CA. 2009. Infection control in cystic fibrosis: Cohorting, crosscontamination, and the respiratory therapist. Respir. Care 54:641-657.
13. Sadikot RT, Blackwell TS, Christman JW, Prince AS. 2005. Pathogenhost interactions in Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 171:1209-1223.
14. Rao J, Damron FH, Basler M, Digiandomenico A, Sherman NE, Fox JW, Mekalanos JJ, Goldberg JB. 2011. Comparisons of two proteomic analyses of non-mucoid and mucoid Pseudomonas aeruginosa clinical isolates from a cystic fibrosis patient. Front. Microbiol. 2:162.
15. Kipnis E, Sawa T, Wiener-Kronish J. 2006. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med. Mal. Infect. 36:78-91.
16. Rosenau F, Isenhardt S, Gdynia A, Tielker D, Schmidt E, Tielen P, Schobert M, Jahn D, Wilhelm S, Jaeger KE. 2010. Lipase LipC affects motility, biofilm formation and rhamnolipid production in Pseudomonas aeruginosa. FEMS Microbiol. Lett. 309:25-34.
17. Tateda K, Ishii Y, Kimura S, Horikawa M, Miyairi S, Yamaguchi K. 2007. Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: A promising strategy or an oriental mystery? J. Infect. Chemother. 13:357-367.
18. Feldman M, Bryan R, Rajan S, Scheffler L, Brunnert S, Tang H, Prince A. 1998. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect. Immun. 66:43-51.
19. Saiman L, Prince A. 1993. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. J. Clin. Invest. 92:1875-1880.
20. Shapiro L. 1995. The bacterial flagellum: From genetic network to complex architecture. Cell 80:525-527.
21. O'Toole GA, Kolter R. 1998. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol. Microbiol. 30:295-304.
22. Caballero AR, Moreau JM, Engel LS, Marquart ME, Hill JM, O'Callaghan RJ. 2001. Pseudomonas aeruginosa protease IV enzyme assays and comparison to other Pseudomonas proteases. Anal. Biochem. 290:330-337.
23. Kanoh S, Rubin BK. 2010. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 23:590-615.
24. Ergin A, Ercis S, Hascelik G. 2006. Macrolide resistance mechanisms and in vitro susceptibility patterns of viridans group streptococci isolated from blood cultures. J. Antimicrob. Chemother. 57:139-141.
25. Sato T, Tateda K, Kimura S, Iwata M, Ishii Y, Yamaguchi K. 2011. In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci. Antimicrob. Agents Chemother. 55:1588-1593.
26. Yanagihara K, Tomono K, Imamura Y, Kaneko Y, Kuroki M, Sawai T, Miyazaki Y, Hirakata Y, Mukae H, Kadota J, Kohno S. 2002. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J. Antimicrob. Chemother. 49:867-870.
27. Moreau-Marquis S, Stanton BA, O'Toole GA. 2008. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm. Pharmacol. Ther. 21:595-599.
28. Makipour K, Friedenberg FK. 2011. The potential role of Nacetylcysteine for the treatment of Helicobacter pylori. J. Clin. Gastroenterol. 45:841-843.
29. Parsek MR, Tolker-Nielsen T. 2008. Pattern formation in Pseudomonas aeruginosa biofilms. Curr. Opin. Microbiol. 11:560-566.
30. Wozniak DJ, Keyser R. 2004. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 125:62S-69S.
31. Callaghan M, McClean S. 2012. Bacterial host interactions in cystic fibrosis. Curr. Opin. Microbiol. 15:71-77.
32. Lieleg O, Ribbeck K. 2011. Biological hydrogels as selective diffusion barriers. Trends Cell Biol. 21:543-551.
33. Khan W, Bernier SP, Kuchma SL, Hammond JH, Hasan F, O'Toole GA. 2010. Aminoglycoside resistance of Pseudomonas aeruginosa biofilms modulated by extracellular polysaccharide. Int. Microbiol. 13:207-212.
34. Mulet X, Macia MD, Mena A, Juan C, Perez JL, Oliver A. 2009. Azithromycin in Pseudomonas aeruginosa biofilms: Bactericidal activity and selection of nfxB mutants. Antimicrob. Agents Chemother. 53:1552-1560.
35. Kawamura-Sato K, Iinuma Y, Hasegawa T, Horii T, Yamashino T, Ohta M. 2000. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob. Agents Chemother. 44:2869-2872.
36. Mugabe C, Halwani M, Azghani AO, Lafrenie RM, Omri A. 2006. Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:2016-2022.
37. Kannan K, Mankin AS. 2011. Macrolide antibiotics in the ribosome exit tunnel: Species-specific binding and action. Ann. N. Y. Acad. Sci. 1241:33-47.
38. Wierzbowski AK, Hoban DJ, Hisanaga T, DeCorby M, Zhanel GG. 2006. The use of macrolides in treatment of upper respiratory tract infections. Curr. Allergy Asthma Rep. 6:171-181.
39. Kohno Y, Ohno H, Miyazaki Y, Higashiyama Y, Yanagihara K, Hirakata Y, Fukushima K, Kohno S. 2007. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob. Agents Chemother. 51:4071-4076.
40. Sandrini A, Balter MS, Chapman KR. 2003. Diffuse panbronchiolitis in a Caucasian man in Canada. Can. Respir. J. 10:449-451.
41. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K, Kohno S. 2003. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir. Med. 97:844-850.
42. Kiran N, Azam S, Dhakam S. 2004. Clarithromycin induced digoxin toxicity: Case report and review. J. Pak. Med. Assoc. 54:440-441.
43. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. 2011. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/Pglycoprotein inhibitors. Arthritis Rheum. 63:2226-2237.
44. Viluksela M, Vainio PJ, Tuominen RK. 1996. Cytotoxicity of macrolide antibiotics in a cultured human liver cell line. J. Antimicrob. Chemother. 38:465-473.
45. Alipour M, Suntres ZE, Omri A. 2009. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 64:317-325.
46. Yang F, Jin C, Jiang Y, Li J, Di Y, Ni Q, Fu D. 2011. Liposome based delivery systems in pancreatic cancer treatment: From bench to bedside. Cancer Treat. Rev. 37:633-642.
47. Jia Y, Joly H, Leek DM, Demetzos C, Omri A. 2010. The effect of aminoglycoside antibiotics on the thermodynamic properties of liposomal vesicles. J. Liposome Res. 20:84-96.
48. Muppidi K, Pumerantz AS, Wang J, Betageri G. 2012. Development and stability studies of novel liposomal vancomycin formulations. ISRN Pharm. 2012:636743. doi:636710.635402/632012/636743.
49. Frezard F, Demicheli C. 2010. New delivery strategies for the old pentavalent antimonial drugs. Expert Opin. Drug Deliv. 7:1343-1358.
50. Halwani M, Yebio B, Suntres ZE, Alipour M, Azghani AO, Omri A. 2008. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 62:1291-1297.
51. Halwani M, Blomme S, Suntres ZE, Alipour M, Azghani AO, Kumar A, Omri A. 2008. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Int. J. Pharm. 358:278-284.
52. Halwani M, Mugabe C, Azghani AO, Lafrenie RM, Kumar A, Omri A. 2007. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J. Antimicrob. Chemother. 60:760-769.
53. Kadry AA, Al-Suwayeh SA, Abd-Allah AR, Bayomi MA. 2004. Treatment of experimental osteomyelitis by liposomal antibiotics. J. Antimicrob. Chemother. 54:1103-1108.
54. Mugabe C, Azghani AO, Omri A. 2005. Liposome-mediated gentamicin delivery: Development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J. Antimicrob. Chemother. 55:269-271.
55. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. 2008. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 61:859-868.
56. Alipour M, Halwani M, Omri A, Suntres ZE. 2008. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int. J. Pharm. 355:293-298.
57. Marier JF, Brazier JL, Lavigne J, Ducharme MP. 2003. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: A pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J. Antimicrob. Chemother. 52:247-252.
58. Onyeji CO, Nightingale CH, Nicolau DP, Quintiliani R. 1994. Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium intracellulare complex in human macrophages. Antimicrob. Agents Chemother. 38:523-527.
59. de Steenwinkel JE, van Vianen W, Ten Kate MT, Verbrugh HA, van Agtmael MA, Schiffelers RM, Bakker-Woudenberg IA. 2007. Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice. J. Antimicrob. Chemother. 60:1064-1073.
60. Jia Y, Joly H, Omri A. 2008. Liposomes as a carrier for gentamicin delivery: Development and evaluation of the physicochemical properties. Int. J. Pharm. 359:254-263.
61. Pumerantz A, Muppidi K, Agnihotri S, Guerra C, Venketaraman V, Wang J, Betageri G. 2011. Preparation of liposomal vancomycin and intracellular killing of meticillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 37:140-144.
62. Alipour M, Suntres ZE, Halwani M, Azghani AO, Omri A. 2009. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS One 4:e5724. doi: 10.1371/journal.pone. 0005724.
63. Rukholm G, Mugabe C, Azghani AO, Omri A. 2006. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: A timekill study. Int. J. Antimicrob. Agents 27:247-252.
64. Anderson M, Omri A. 2004. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Deliv. 11:33-39.
65. Halwani M, Hebert S, Suntres ZE, Lafrenie RM, Azghani AO, Omri A. 2009. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa. Int. J. Pharm. 373:141-146.
66. Mugabe C, Azghani AO, Omri A. 2006. Preparation and characterization of dehydration-rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. Int. J. Pharm. 307:244-250.
67. Alipour M, Omri A, Suntres ZE. 2011. Ginseng aqueous extract attenuates the production of virulence factors, stimulates twitching and adhesion, and eradicates biofilms of Pseudomonas aeruginosa. Can. J. Physiol. Pharmacol. 89:419-427.
68. Alipour M, Suntres ZE, Lafrenie RM, Omri A. 2010. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by coencapsulation of bismuth-ethanedithiol with tobramycin in liposomes. J. Antimicrob. Chemother. 65:684-693.
69. Vuong C, Gotz F, Otto M. 2000. Construction and characterization of an agr deletion mutant of Staphylococcus epidermidis. Infect. Immun. 68: 1048-1053.
70. Allan ND, Kooi C, Sokol PA, Beveridge TJ. 2003. Putative virulence factors are released in association with membrane vesicles from Burkholderia cepacia. Can. J. Microbiol. 49:613-624.
71. Folders J, Algra J, Roelofs MS, van Loon LC, Tommassen J, Bitter W. 2001. Characterization of Pseudomonas aeruginosa chitinase, a gradually secreted protein. J. Bacteriol. 183:7044-7052.
72. Winson MK, Camara M, Latifi A, Foglino M, Chhabra SR, Daykin M, Bally M, Chapon V, Salmond GP, Bycroft BW, et al. 1995. Multiple N-acyl-L-homoserine lactone signal molecules regulate production of virulence determinants and secondary metabolites in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 92:9427-9431.
73. Kessler E, Safrin M, Olson JC, Ohman DE. 1993. Secreted LasA of Pseudomonas aeruginosa is a staphylolytic protease. J. Biol. Chem. 268: 7503-7508.
74. Kong HS, Roberts DP, Patterson CD, Kuehne SA, Heeb S, Lakshman DK, Lydon J. 2012. Effect of overexpressing rsmA from Pseudomonas aeruginosa on virulence of select phytotoxin-producing strains of P. syringae. Phytopathology 102:575-587.
75. Nombona N, Maduray K, Antunes E, Karsten A, Nyokong T. 2012. Synthesis of phthalocyanine conjugates with gold nanoparticles and liposomes for photodynamic therapy. J. Photochem. Photobiol. B 107:35-44.
76. Lawrence SM, Alpar HO, McAllister SM, Brown MR. 1993. Liposomal (MLV) polymyxin B: Physicochemical characterization and effect of surface charge and drug association. J. Drug Target. 1:303-310.
77. Hosny KM. 2010. Ciprofloxacin as ocular liposomal hydrogel. AAPS PharmSciTech. 11:241-246.
78. Kadar B, Szasz M, Kristof K, Pesti N, Krizsan G, Szentandrassy J, Rokusz L, Nagy K, Szabo D. 2010. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains. Acta Microbiol. Immunol. Hung. 57: 235-245.
79. Gubernator J, Drulis-Kawa Z, Dorotkiewicz-Jach A, Doroszkiewicz W, Kozubek A. 2007. In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gram-negative clinical bacterial strains. Lett. Drug Design Discov. 4:297-304.
80. Yasuda H, Ajiki Y, Koga T, Kawada H, Yokota T. 1993. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob. Agents Chemother. 37:1749-1755.
81. Tre-Hardy M, Vanderbist F, Traore H, Devleeschouwer MJ. 2008. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. Int. J. Antimicrob. Agents 31:329-336.
82. Alipour M, Dorval C, Suntres ZE, Omri A. 2011. Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa. J. Pharm. Pharmacol. 63:999-1007.
83. Molinari G, Paglia P, Schito GC. 1992. Inhibition of motility of Pseudomonas aeruginosa and Proteus mirabilis by subinhibitory concentrations of azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 11:469-471.
84. Casadevall A, Pirofski LA. 2009. Virulence factors and their mechanisms of action: The view from a damage-response framework. J. Water Health 7(Suppl. 1):S2-S18.
85. Lyczak JB, Cannon CL, Pier GB. 2000. Establishment of Pseudomonas aeruginosa infection: Lessons from a versatile opportunist. Microbes Infect. 2:1051-1060.
86. Skindersoe ME, Alhede M, Phipps R, Yang L, Jensen PO, Rasmussen TB, Bjarnsholt T, Tolker-Nielsen T, Hoiby N, Givskov M. 2008. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52:3648-3663.
87. Garey KW, Vo QP, Lewis RE, Saengcharoen W, LaRocco MT, Tam VH. 2009. Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. Diagn. Microbiol. Infect. Dis. 63:81-86.
88. Molinari G, Guzman CA, Pesce A, Schito GC. 1993. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother. 31:681-688.
89. Filion MC, Phillips NC. 1997. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim. Biophys. Acta 1329:345-356.
90. Lappalainen K, Jaaskelainen I, Syrjanen K, Urtti A, Syrjanen S. 1994. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm. Res. 11:1127-1131.
91. Manosroi A, Thathang K, Werner RG, Schubert R, Peschka-Suss R, Manosroi J. 2008. Development of highly stable and low toxic cationic liposomes for gene therapy. Arzneimittelforschung 58:485-492.